Serous tubal intraepithelial carcinoma and the dominant ovarian mass: Clues to serous tumor origin?

American Journal of Surgical Pathology

Volumn 33, Issue 3, 2009, Pages 376-383

  Roh, Michael H ^a   Kindelberger, David ^a   Crum, Christopher P ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Amory 3 127 ^*  (United States)

Author keywords

Endometrioid carcinoma; Ovarian cancer; Serous carcinoma; Tubal intraepithelial carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PELVIS CANCER; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; CARCINOMA IN SITU; CYSTADENOCARCINOMA; METABOLISM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; UTERINE TUBE TUMOR;

CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 62849095422     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181868904     Document Type: Article

References (35)

1. Alvarado-Cabrero I, Cheung A, Caduff R. Tumours of the fallopian tube. In: Tavassoli FA, Devilee P, eds. Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours. Lyon: IARC Press; 2003:206-209.
2. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000; 89:383-390.
3. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer. 1994;73:1859-1864.
4. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337.
5. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.
6. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30:1222-1230.
7. Carlson J, Roh MH, Chang MC, et al. Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low and high grade disease and the role of the Fallopian tube. Diagn Histopathol. In press.
8. Carlson JW, Miron A, Jarboe E, et al. Serous tubal intraepithelial carcinoma (STIC): its potential role in primary peritoneal serous carcinoma (PPSC) and serous cancer prevention. J Clin Oncol. In press.
9. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-1334.
10. Chang PS, Crum CP. The fallopian tube and broad ligament. In: Crum CP, Lee KR, eds. Diagnostic Gynecologic and Obstetric Pathology. Philadelphia: Elsevier Saunders; 2006:698-701.
11. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-333.
12. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001; 25:1283-1289.
13. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9.
14. Deligdisch L, Gil J, Kerner H, et al. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer. 1999;86:1544-1550.
15. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64.
16. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with heterozygous BRCA mutations. Gynecol Oncol. 2008;109:168-173.
17. Horiuchi A, Itoh K, Shimizu M, et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopatho-logical approach. Gynecol Oncol. 2003;88:309-317.
18. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology. 1995; 27:367-371.
19. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2007;31:161-169.
20. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
21. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
22. Lee KR, Tavassoli FA, Prat J, et al. Surface epithelial-stromal tumors. In: Tavassoli FA, Devilee P, eds. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:119-120.
23. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
24. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-4227.
25. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familiar ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
26. Mhawech P, Kinkel K, Vlastos G, et al. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study. Int J Gynecol Pathol. 2002;21: 401-406.
27. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773-779.
28. Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol. 2003;109:97-101.
29. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001;80:176-180.
30. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004;191:718-732.
31. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23: 127-132.
32. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2003;23:41-44.
33. Singer G, Stohr R, Cope L, Dehari R, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol. 2005;29: 218-224.
34. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol. 2004;23:29-34.
35. Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol. 2000;76:45-50.